Globus Medical GMED has experienced strong upward momentum in the past year, with its shares rising 41.8%. This has far outpaced the industry’s 7.5% decline and the S&P 500 composite’s 8.8% growth.

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Globus Medical's results underscore a strong quarter, with effective execution of strategic initiatives, notably the full integration of the September 2023 NuVasive merger. Globus Medical offers ...

Globus Medical, Inc. GMED reported fourth-quarter ... Net sales improvement was driven by the addition of NuVasive, as well as increased volume of spine product sales and enabling technology ...

We have yet to fully harness the power of the combined Globus NuVasive product offering internationally and feel this will be a significant tailwind as we move forward in 2025 and beyond.

On September 1st, 2023, NuVasive was acquired by Globus Medical, a U.S.-based company specialized in musculoskeletal devices and implants2. In view of their different strategic orientations ...

AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

The performance reflects the strong potential of the combined Globus-NuVasive organization and the growing value creation from the merger. Impressively, the company registered the highest ...